CHD5 is down-regulated through promoter hypermethylation in gastric cancer

Journal of Biomedical Science

Volumn 16, Issue 1, 2009, Pages

  Wang, Xian ^a,b   Lau, Kenneth Kk ^a   So, Leo Ky ^a,c   Lam, Yun Wah ^a  

^a CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; DNA BINDING PROTEIN; UNCLASSIFIED DRUG; CHD5 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HELICASE; HETEROCYCLIC COMPOUND; NERVE PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CLINICAL EVALUATION; COLONY FORMATION; CONTROLLED STUDY; DEMETHYLATION; GENE EXPRESSION; GENE SEQUENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOMA; BIOSYNTHESIS; CHEMISTRY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

AZA COMPOUNDS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA HELICASES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 70450225479     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-16-95     Document Type: Article

References (26)

1. What histone code for DNA repair? AE Escargueil DG Soares M Salvador AK Larsen JA Henriques, Mutat Res 2008 658 3 259 270 10.1016/j.mrrev.2008.01.004 18296106
2. Chromatin domains and regulation of transcription. SV Razin OV Iarovaia N Sjakste T Sjakste L Bagdoniene AV Rynditch ER Eivazova M Lipinski YS Vassetzky, J Mol Biol 2007 369 3 597 607 10.1016/j.jmb.2007.04.003 17466329
3. [Histone modification enzymes]. K Sasaki M Yoshida, Tanpakushitsu Kakusan Koso 2006 51 14 Suppl 2069 2075 17471912
4. The histone code at DNA breaks: a guide to repair? H van Attikum SM Gasser, Nat Rev Mol Cell Biol 2005 6 10 757 765 10.1038/nrm1737 16167054
5. Histone acetylation and transcriptional regulatory mechanisms. K Struhl, Genes Dev 1998 12 5 599 606 10.1101/gad.12.5.599 9499396
6. [Variations on the topic of the "histone code"]. D Ray-Gallet A Gerard S Polo G Almouzni, Med Sci (Paris) 2005 21 4 384 389 15811303
7. Functional consequences of histone modifications. M Iizuka MM Smith, Curr Opin Genet Dev 2003 13 2 154 160 10.1016/S0959-437X(03)00020-0 12672492
8. Histone modifications in transcriptional regulation. SL Berger, Curr Opin Genet Dev 2002 12 2 142 148 10.1016/S0959-437X(02)00279-4 11893486
9. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. J Pallos L Bodai T Lukacsovich JM Purcell JS Steffan LM Thompson JL Marsh, Hum Mol Genet 2008 17 23 3767 3775 10.1093/hmg/ddn273 18762557
10. HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. D Wegener HE Deubzer I Oehme T Milde C Hildmann A Schwienhorst O Witt, Anticancer Drugs 2008 19 9 849 857 10.1097/CAD.0b013e32830efbeb 18765999
11. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Q Zhou PG Shaw NE Davidson, Breast Cancer Res Treat 2008 117 2 443 51 10.1007/s10549-008-0148- 5 18683042
12. Targeted knockout of BRG1 potentiates lung cancer development. S Glaros GM Cirrincione A Palanca D Metzger D Reisman, Cancer Res 2008 68 10 3689 3696 10.1158/0008-5472.CAN-07-6652 18483251
13. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. PP Medina M Sanchez-Cespedes, Epigenetics 2008 3 2 64 68 18437052
14. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. PM Thompson T Gotoh M Kok PS White GM Brodeur, Oncogene 2003 22 7 1002 1011 10.1038/sj.onc.1206211 12592387
15. CHD5 is a tumor suppressor at human 1p36. A Bagchi C Papazoglu Y Wu D Capurso M Brodt D Francis M Bredel H Vogel AA Mills, Cell 2007 128 3 459 475 10.1016/j.cell.2006.11.052 17289567
16. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. PS White PM Thompson T Gotoh ER Okawa J Igarashi M Kok C Winter SG Gregory MD Hogarty JM Maris. et al. Oncogene 2005 24 16 2684 2694 10.1038/sj.onc.1208306 15829979
17. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. KL Gorringe DY Choong LH Williams M Ramakrishna A Sridhar W Qiu JL Bearfoot IG Campbell, Neoplasia 2008 10 11 1253 1258 18953434
18. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. R Beroukhim G Getz L Nghiemphu J Barretina T Hsueh D Linhart I Vivanco JC Lee JH Huang S Alexander. et al. Proc Natl Acad Sci USA 2007 104 50 20007 20012 10.1073/pnas.0710052104 18077431
19. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. T Fujita J Igarashi ER Okawa T Gotoh J Manne V Kolla J Kim H Zhao BR Pawel WB London. et al. J Natl Cancer Inst 2008 100 13 940 949 10.1093/jnci/djn176 18577749
20. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. S Mulero-Navarro M Esteller, Epigenetics 2008 3 4 210 215 18698156
21. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. LJ Wang HC Jin X Wang EK Lam JB Zhang X Liu FK Chan JM Si JJ Sung, Biochem Biophys Res Commun 2009 379 4 959 963 10.1016/j.bbrc.2008.12.180 19135984
22. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. YY Cheng H Jin X Liu JM Siu YP Wong EK Ng J Yu WK Leung JJ Sung FK Chan, Br J Cancer 2008 99 12 2083 7 10.1038/sj.bjc.6604760 18985039
23. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. P Vogiatzi C Vindigni F Roviello A Renieri A Giordano, J Cell Physiol 2007 211 2 287 295 10.1002/jcp.20982 17238139
24. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. J Yu Q Tao KF Cheung H Jin FF Poon X Wang H Li YY Cheng C Rocken MP Ebert. et al. Hepatology 2008 48 2 508 518 10.1002/hep.22343 18666234
25. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. G Tamura, Histol Histopathol 2004 19 1 221 228 14702190
26. Chromosomal imbalances in gastric cancer. Correlation with histologic subtypes and tumor progression. T Noguchi HC Wirtz S Michaelis HE Gabbert W Mueller, Am J Clin Pathol 2001 115 6 828 834 10.1309/2Q9E-3EP5-KYPK-VFGQ 11392878